Healthy Volunteer Study Clinical Trial
Official title:
A Randomised, Double-blind Placebo-controlled Study to Assess the Safety of Four Single Ascending Doses of HF1020 in Healthy Male Subjects
The study aims to:
- study the safety of the drug (HF1020) in healthy male adults
- study how well the study drug (HF1020) is tolerated in healthy male adults
- find the maximum dose that is tolerated in healthy male adults
This is a single-centre, randomised, double-blind, placebo-controlled, ascending dose study.
Male subjects will be randomised to give a total of 32 evaluable subjects.
Subjects will be sequentially enrolled into 4 cohorts of ascending dose.
Subjects in Cohort 1 will be randomised to receive 0.5 milligrams (mg) HF1020 or placebo
(ratio 3:1). When at least 8 subjects within the cohort have completed Day 2 procedures
(i.e. Day 1 + 24 hours) and all ongoing subjects have completed the final Day 15 visit, a
Safety Review Committee (SRC) will meet, review all safety data prior to dose escalation to
the next cohort.
Subjects in Cohort 2 will be randomised to receive 2.5 mg HF1020 or placebo.
Subjects in Cohort 3 will be randomised to receive 10mg HF1020 or placebo.
Subjects in Cohort 4 will be randomised to receive 25mg HF1020 or placebo.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03270878 -
Glasdegib Absolute Bioavailability Study
|
Phase 1 | |
Completed |
NCT03777488 -
Pharmacokinetics of Tranexamic Acid After Oral, Intramuscular or Intravenous Administration: a Prospective, Randomised, Cross-over Trial in Healthy Volunteers.
|
Phase 1 | |
Completed |
NCT03086278 -
A Study of AST-008 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04711187 -
Study of AT-527 in Healthy Subjects (R07496998)
|
Phase 1 | |
Completed |
NCT06141889 -
Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05154123 -
Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)
|
Phase 1 | |
Completed |
NCT05179421 -
Dose Ranging Study of Intravenous Oxytocin for Analgesia to Heat Pain
|
Phase 2 | |
Completed |
NCT03945344 -
Effect of Charcoal on Gastrointestinal Absorption of Tiotropium
|
Phase 1 | |
Recruiting |
NCT05881993 -
Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects
|
Early Phase 1 | |
Completed |
NCT04242953 -
Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects
|
Phase 1 | |
Completed |
NCT02393950 -
Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00866385 -
AZD8566 Food Effect/Microtracer Study
|
Phase 1 | |
Completed |
NCT04784000 -
Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527
|
Phase 1 | |
Completed |
NCT01609218 -
A Study of LY2140023 in Healthy Participants
|
Phase 1 | |
Completed |
NCT02503085 -
Ibuprofen Suspension Bioequivalence Study
|
Phase 1 | |
Completed |
NCT05004415 -
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
|
Phase 1 | |
Completed |
NCT02256423 -
A Study Comparing Three Formulations of Ibuprofen in Healthy Subjects
|
Phase 1 | |
Completed |
NCT05731843 -
Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir
|
Phase 1 | |
Completed |
NCT03031535 -
Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT02452450 -
Ibuprofen and Paracetamol Pharmacokinetic Study
|
Phase 1 |